Last reviewed · How we verify
NCT03508063
Monitoring Changes in Physiological Parameters by Utilization of the Combined Physiological Activity Index (CPAI)
trial in Healthy Subjects in 70 participants. Completed in 21 May 2018.
21 May 2018
Quick facts
| Lead sponsor | Medasense Biometrics Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 20 December 2017 |
| Primary completion | 21 May 2018 |
| Estimated completion | 21 May 2018 |
| Sites | 1 location across Israel |
Conditions studied
- Healthy Subjects — all drugs for Healthy Subjects →
Sponsor
Medasense Biometrics Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A clinical trial to validate the MCPM (Multi-parameter Combined Physiological Signal-based Monitoring), in estimating physiological activity level, at rest, previous and following stimuli.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03508063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Subjects
Currently open trials in the same condition.
- NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
- NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
- NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
- NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
- NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting
Other Medasense Biometrics Ltd trials
Trials by the same sponsor.
- NCT04305015 — Postoperative Benefits of Intraoperative Nociception Level (NOL) Titration - Pilot · NA · completed
- NCT04581642 — Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report · completed
- NCT03970291 — Impact of NOL Intraoperative Guided Fentanyl Analgesia vs SCC for Elective Major Abdominal Surgery · NA · completed
- NCT03452163 — Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit · NA · terminated
- NCT03389048 — Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03508063 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medasense Biometrics Ltd
- Last refreshed: 8 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03508063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing